Could Artiva’s NK cells drive cell therapy-like activity with biologics-like ease of use?

Time: 10:00 am
day: Conference Day 1 P1

Details:

• Highlight the rationale and potential advantages of utilizing a non-genetically modified NK cell therapy in combination with monoclonal antibodies in autoimmune diseases
• Explore clinical data demonstrating that NK cell therapies can drive deep B-cell depletion in autoimmune disease while avoiding side effects inherent in CAR-T and TCE therapies
• Highlight a framework for selecting indications for different cell therapies based on their potential target product profile

Speakers:

Fred Aslan Fred Aslan, M.D. brings two decades of leadership in the life sciences industry as an executive, investor, and entrepreneur. Most recently, he served as President Read more